Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024
Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage developmen...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal Article |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier
2025
|
| Materias: | |
| Acceso en línea: | https://hdl.handle.net/10568/173751 |
| _version_ | 1855517635135930368 |
|---|---|
| author | Gharpure, R. Vegvari, C. Abdissa, A. Alimi, Y. Anyamba, A. Auerbach, J. Bett, Bernard K. Bird, B.H. Bob, N.S. Breugelmans, J.G. Clark, J. Cleaveland, S. Cramer, J. Dawa, J. Fay, P.C. Formenty, P. Gerdts, V. Gerken, Keli N. Gitonga, J. Groschup, M. Heighway, J. Johnson, S.A.M. Juma, John Kading, R.C. Kamau, M. Kerama, S. Lubisi, B.A. Lutwama, J. Luyimbazi, D. Marami, D. Moore, S.M. Muturi, M. Mwangoka, G. Ndiu, A. Njenga, M.K. Njouom, R. Nyakarahuka, L. Nzietchueng, S. Oloo, P. Otiende, M. Oyola, Samuel O. Paganini, L.S. Pandit, P.S. Punt, C. Samy, A.M. Situma, S. Sneddon, H. Bosch, Q.A. ten Tezcan-Ulger, S. Thompson, P.N. Tildesley, M. Tinto, B. Vesga, J.F. Wichgers Schreur, P.P. Hart, P. |
| author_browse | Abdissa, A. Alimi, Y. Anyamba, A. Auerbach, J. Bett, Bernard K. Bird, B.H. Bob, N.S. Bosch, Q.A. ten Breugelmans, J.G. Clark, J. Cleaveland, S. Cramer, J. Dawa, J. Fay, P.C. Formenty, P. Gerdts, V. Gerken, Keli N. Gharpure, R. Gitonga, J. Groschup, M. Hart, P. Heighway, J. Johnson, S.A.M. Juma, John Kading, R.C. Kamau, M. Kerama, S. Lubisi, B.A. Lutwama, J. Luyimbazi, D. Marami, D. Moore, S.M. Muturi, M. Mwangoka, G. Ndiu, A. Njenga, M.K. Njouom, R. Nyakarahuka, L. Nzietchueng, S. Oloo, P. Otiende, M. Oyola, Samuel O. Paganini, L.S. Pandit, P.S. Punt, C. Samy, A.M. Situma, S. Sneddon, H. Tezcan-Ulger, S. Thompson, P.N. Tildesley, M. Tinto, B. Vegvari, C. Vesga, J.F. Wichgers Schreur, P.P. |
| author_facet | Gharpure, R. Vegvari, C. Abdissa, A. Alimi, Y. Anyamba, A. Auerbach, J. Bett, Bernard K. Bird, B.H. Bob, N.S. Breugelmans, J.G. Clark, J. Cleaveland, S. Cramer, J. Dawa, J. Fay, P.C. Formenty, P. Gerdts, V. Gerken, Keli N. Gitonga, J. Groschup, M. Heighway, J. Johnson, S.A.M. Juma, John Kading, R.C. Kamau, M. Kerama, S. Lubisi, B.A. Lutwama, J. Luyimbazi, D. Marami, D. Moore, S.M. Muturi, M. Mwangoka, G. Ndiu, A. Njenga, M.K. Njouom, R. Nyakarahuka, L. Nzietchueng, S. Oloo, P. Otiende, M. Oyola, Samuel O. Paganini, L.S. Pandit, P.S. Punt, C. Samy, A.M. Situma, S. Sneddon, H. Bosch, Q.A. ten Tezcan-Ulger, S. Thompson, P.N. Tildesley, M. Tinto, B. Vesga, J.F. Wichgers Schreur, P.P. Hart, P. |
| author_sort | Gharpure, R. |
| collection | Repository of Agricultural Research Outputs (CGSpace) |
| description | Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage development. Existing gaps in RVF epidemiological data and challenges associated with predicting RVF outbreak risk complicate the planning of efficacy studies, making the pathway to licensure for promising candidates unclear. In June 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) convened a two-day workshop in Nairobi, Kenya, to discuss RVF epidemiology, modeling priorities, and specific gaps relevant to human RVF vaccine development. The workshop included representatives from multiple RVF-endemic countries, key global collaborators, and international health organizations.
Workshop participants identified five key priorities: (1) <b>Looking beyond outbreaks</b>: There is a need to better characterize the complex One Health epidemiology of RVF and understand interepidemic persistence of the virus; (2) <b>Better data for better models</b>: Epidemiological modeling is crucial for research, prediction, and planning, but it requires accurate and representative data; (3) <b>New, improved and accessible diagnostics and serological assays</b>: These are needed to inform epidemiology and case definitions, without which RVF research will continue to suffer due to paucity of data and challenges in determining infection and exposure; (4) <b>Defining use cases, regulatory pathways, and implementation strategies for human vaccines</b>: Clarity on these topics will facilitate licensure and effective use of RVF vaccines; and (5) <b>People-centered approaches</b>: Community engagement and involvement of social and behavioral scientists are key to the success of human vaccine research and development and implementation, particularly as the virus impacts livestock and livelihoods.
Workshop participants welcomed a renewed focus for RVF epidemiology and modeling, and expressed enthusiasm for continued multidisciplinary collaborations to support enabling sciences for human RVF vaccine research and development. |
| format | Journal Article |
| id | CGSpace173751 |
| institution | CGIAR Consortium |
| language | Inglés |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | Elsevier |
| publisherStr | Elsevier |
| record_format | dspace |
| spelling | CGSpace1737512025-12-08T09:54:28Z Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 Gharpure, R. Vegvari, C. Abdissa, A. Alimi, Y. Anyamba, A. Auerbach, J. Bett, Bernard K. Bird, B.H. Bob, N.S. Breugelmans, J.G. Clark, J. Cleaveland, S. Cramer, J. Dawa, J. Fay, P.C. Formenty, P. Gerdts, V. Gerken, Keli N. Gitonga, J. Groschup, M. Heighway, J. Johnson, S.A.M. Juma, John Kading, R.C. Kamau, M. Kerama, S. Lubisi, B.A. Lutwama, J. Luyimbazi, D. Marami, D. Moore, S.M. Muturi, M. Mwangoka, G. Ndiu, A. Njenga, M.K. Njouom, R. Nyakarahuka, L. Nzietchueng, S. Oloo, P. Otiende, M. Oyola, Samuel O. Paganini, L.S. Pandit, P.S. Punt, C. Samy, A.M. Situma, S. Sneddon, H. Bosch, Q.A. ten Tezcan-Ulger, S. Thompson, P.N. Tildesley, M. Tinto, B. Vesga, J.F. Wichgers Schreur, P.P. Hart, P. diagnosis epidemiology rift valley fever vaccines zoonoses Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage development. Existing gaps in RVF epidemiological data and challenges associated with predicting RVF outbreak risk complicate the planning of efficacy studies, making the pathway to licensure for promising candidates unclear. In June 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) convened a two-day workshop in Nairobi, Kenya, to discuss RVF epidemiology, modeling priorities, and specific gaps relevant to human RVF vaccine development. The workshop included representatives from multiple RVF-endemic countries, key global collaborators, and international health organizations. Workshop participants identified five key priorities: (1) <b>Looking beyond outbreaks</b>: There is a need to better characterize the complex One Health epidemiology of RVF and understand interepidemic persistence of the virus; (2) <b>Better data for better models</b>: Epidemiological modeling is crucial for research, prediction, and planning, but it requires accurate and representative data; (3) <b>New, improved and accessible diagnostics and serological assays</b>: These are needed to inform epidemiology and case definitions, without which RVF research will continue to suffer due to paucity of data and challenges in determining infection and exposure; (4) <b>Defining use cases, regulatory pathways, and implementation strategies for human vaccines</b>: Clarity on these topics will facilitate licensure and effective use of RVF vaccines; and (5) <b>People-centered approaches</b>: Community engagement and involvement of social and behavioral scientists are key to the success of human vaccine research and development and implementation, particularly as the virus impacts livestock and livelihoods. Workshop participants welcomed a renewed focus for RVF epidemiology and modeling, and expressed enthusiasm for continued multidisciplinary collaborations to support enabling sciences for human RVF vaccine research and development. 2025-04 2025-03-20T11:41:56Z 2025-03-20T11:41:56Z Journal Article https://hdl.handle.net/10568/173751 en Open Access Elsevier Gharpure, R., Vegvari, C., Abdissa, A., Alimi, Y., Anyamba, A., Auerbach, J., Bett, B., Bird, B.H., Bob, N.S., Breugelmans, J.G., Clark, J., Cleaveland, S., Cramer, J., Dawa, J., Fay, P.C., Formenty, P., Gerdts, V., Gerken, K.N., Gitonga, J., Groschup, M., Heighway, J., Johnson, S.A.M., Juma, J., Kading, R.C., Kamau, M., Kerama, S., Lubisi, B.A., Lutwama, J., Luyimbazi, D., Marami, D., Moore, S.M., Muturi, M., Mwangoka, G., Ndiu, A., Njenga, M.K., Njouom, R., Nyakarahuka, L., Nzietchueng, S., Oloo, P., Otiende, M., Oyola, S., Paganini, L.S., Pandit, P.S., Punt, C., Samy, A.M., Situma, S., Sneddon, H., Bosch, Q.A. ten, Tezcan-Ulger, S., Thompson, P.N., Tildesley, M., Tinto, B., Vesga, J.F., Wichgers Schreur, P.P. and Hart, P. 2025. Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024. Vaccine 54: 126860. |
| spellingShingle | diagnosis epidemiology rift valley fever vaccines zoonoses Gharpure, R. Vegvari, C. Abdissa, A. Alimi, Y. Anyamba, A. Auerbach, J. Bett, Bernard K. Bird, B.H. Bob, N.S. Breugelmans, J.G. Clark, J. Cleaveland, S. Cramer, J. Dawa, J. Fay, P.C. Formenty, P. Gerdts, V. Gerken, Keli N. Gitonga, J. Groschup, M. Heighway, J. Johnson, S.A.M. Juma, John Kading, R.C. Kamau, M. Kerama, S. Lubisi, B.A. Lutwama, J. Luyimbazi, D. Marami, D. Moore, S.M. Muturi, M. Mwangoka, G. Ndiu, A. Njenga, M.K. Njouom, R. Nyakarahuka, L. Nzietchueng, S. Oloo, P. Otiende, M. Oyola, Samuel O. Paganini, L.S. Pandit, P.S. Punt, C. Samy, A.M. Situma, S. Sneddon, H. Bosch, Q.A. ten Tezcan-Ulger, S. Thompson, P.N. Tildesley, M. Tinto, B. Vesga, J.F. Wichgers Schreur, P.P. Hart, P. Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 |
| title | Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 |
| title_full | Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 |
| title_fullStr | Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 |
| title_full_unstemmed | Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 |
| title_short | Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024 |
| title_sort | meeting report cepi workshop on rift valley fever epidemiology and modeling to inform human vaccine development nairobi 4 5 june 2024 |
| topic | diagnosis epidemiology rift valley fever vaccines zoonoses |
| url | https://hdl.handle.net/10568/173751 |
| work_keys_str_mv | AT gharpurer meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT vegvaric meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT abdissaa meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT alimiy meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT anyambaa meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT auerbachj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT bettbernardk meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT birdbh meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT bobns meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT breugelmansjg meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT clarkj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT cleavelands meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT cramerj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT dawaj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT faypc meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT formentyp meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT gerdtsv meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT gerkenkelin meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT gitongaj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT groschupm meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT heighwayj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT johnsonsam meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT jumajohn meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT kadingrc meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT kamaum meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT keramas meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT lubisiba meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT lutwamaj meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT luyimbazid meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT maramid meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT mooresm meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT muturim meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT mwangokag meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT ndiua meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT njengamk meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT njouomr meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT nyakarahukal meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT nzietchuengs meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT oloop meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT otiendem meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT oyolasamuelo meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT paganinils meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT panditps meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT puntc meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT samyam meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT situmas meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT sneddonh meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT boschqaten meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT tezcanulgers meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT thompsonpn meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT tildesleym meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT tintob meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT vesgajf meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT wichgersschreurpp meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 AT hartp meetingreportcepiworkshoponriftvalleyfeverepidemiologyandmodelingtoinformhumanvaccinedevelopmentnairobi45june2024 |